Ratings by Mizuho (Graig Suvannavejh)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/2/2024 | Immuneering Corporation | IMRX | Maintain | Buy (N/A) |
|
Details | ||
| 3/28/2024 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2024 | Amylyx Pharmaceuticals inc. | AMLX | Downgrade | Neutral (Buy) |
3.17 (2.07) |
-34.7% | Details | |
| 3/8/2024 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2024 | Immunocore Holdings | IMCR | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Immunocore Holdings | IMCR | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 2/15/2024 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 2/15/2024 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 2/9/2024 | Verastem | VSTM | New Coverage | Buy (N/A) |
13.45 (11.07) |
-17.7% | Details | |
| 2/9/2024 | Immuneering Corporation | IMRX | New Coverage | Buy (N/A) |
6.09 (1.92) |
-68.47% | Details | |
| 2/9/2024 | Erasca Inc | ERAS | New Coverage | Buy (N/A) |
1.76 (2.00) |
13.64% | Details | |
| 2/9/2024 | Corvus Pharmaceuticals | CRVS | New Coverage | Neutral (N/A) |
2.00 (1.47) |
-26.5% | Details | |
| 2/9/2024 | Adaptimmune Therapeutics plc | ADAP | New Coverage | Buy (N/A) |
1.15 (1.05) |
-8.7% | Details | |
| 2/6/2024 | Adverum Biotechnologies | ADVM | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 12/7/2023 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Buy (N/A) |
|
Details | ||
| 11/27/2023 | Terns Pharmaceuticals | TERN | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2023 | Alector Inc. | ALEC | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2023 | Immunocore Holdings | IMCR | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2023 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 11/13/2023 | Apellis Pharmaceuticals | APLS | Maintain | Neutral (N/A) |
|
Details | ||
| 11/6/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 11/3/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2023 | EyePoint Pharmaceuticals, Inc. | EYPT | New Coverage | Buy (N/A) |
6.02 (21.28) |
253.49% | Details | |
| 11/2/2023 | Apellis Pharmaceuticals | APLS | New Coverage | Neutral (N/A) |
48.66 (51.50) |
5.84% | Details | |
| 10/27/2023 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 10/19/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 10/19/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 9/6/2023 | Insmed | INSM | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2023 | BioXcel Therapeutics | BTAI | Downgrade | Neutral (Buy) |
4.33 (2.75) |
-36.49% | Details | |
| 8/11/2023 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 8/11/2023 | Alector Inc. | ALEC | Maintain | Buy (N/A) |
|
Details | ||
| 8/10/2023 | Vigil Neuroscience Inc | VIGL | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Terns Pharmaceuticals | TERN | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2023 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 6/22/2023 | Terns Pharmaceuticals | TERN | New Coverage | Buy (N/A) |
11.74 (5.06) |
-56.9% | Details | |
| 6/5/2023 | Rain Therapeutics | RAIN | Downgrade | Neutral (Buy) |
1.11 (1.21) |
9.01% | Details | |
| 5/15/2023 | Athira Pharma | ATHA | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2023 | Amylyx Pharmaceuticals inc. | AMLX | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2023 | Immunocore Holdings | IMCR | Maintain | Buy (N/A) |
|
Details | ||
| 5/11/2023 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 5/8/2023 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2023 | Amylyx Pharmaceuticals inc. | AMLX | New Coverage | Buy (N/A) |
29.19 (2.07) |
-92.91% | Details | |
| 3/31/2023 | Immunocore Holdings | IMCR | New Coverage | Buy (N/A) |
47.86 (55.54) |
16.05% | Details | |
| 3/31/2023 | Vigil Neuroscience Inc | VIGL | New Coverage | Buy (N/A) |
10.40 (3.16) |
-69.62% | Details | |
| 3/31/2023 | Immatics | IMTX | New Coverage | Buy (N/A) |
7.53 (10.40) |
38.11% | Details | |
| 3/29/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2023 | Rain Therapeutics | RAIN | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2023 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/3/2023 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2023 | Alector Inc. | ALEC | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2023 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2023 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 2/9/2023 | Rain Therapeutics | RAIN | Maintain | Buy (N/A) |
|
Details | ||
| 2/8/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2023 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 1/23/2023 | Rain Therapeutics | RAIN | New Coverage | Buy (N/A) |
8.75 (1.21) |
-86.17% | Details | |
| 12/15/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2022 | Insmed | INSM | New Coverage | Buy (N/A) |
18.93 (26.82) |
41.68% | Details | |
| 11/16/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 11/9/2022 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/9/2022 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 9/12/2022 | Alector Inc. | ALEC | Maintain | Buy (N/A) |
|
Details | ||
| 9/7/2022 | Axsome Therapeutics | AXSM | New Coverage | Buy (N/A) |
60.79 (68.21) |
12.21% | Details | |
| 8/23/2022 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2022 | Harmony Biosciences Holdings Inc. | HRMY | Maintain | Buy (N/A) |
|
Details | ||
| 8/3/2022 | Cerevel Therapeutics | CERE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/8/2022 | Alector Inc. | ALEC | Maintain | Buy (N/A) |
|
Details | ||
| 7/7/2022 | Intra-Cellular Therapies | ITCI | New Coverage | Buy (N/A) |
57.09 (64.76) |
13.43% | Details | |
| 7/7/2022 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
14.64 (2.75) |
-81.22% | Details | |
| 7/7/2022 | Athira Pharma | ATHA | New Coverage | Buy (N/A) |
3.43 (2.06) |
-39.94% | Details | |
| 7/7/2022 | Cerevel Therapeutics | CERE | New Coverage | Neutral (N/A) |
30.63 (41.70) |
36.14% | Details | |
| 7/7/2022 | Alector Inc. | ALEC | New Coverage | Buy (N/A) |
11.64 (5.64) |
-51.55% | Details | |
| 7/7/2022 | Harmony Biosciences Holdings Inc. | HRMY | New Coverage | Buy (N/A) |
52.65 (29.52) |
-43.93% | Details |
